Pre-launch strategy

The pre-launch challenge

Medical affairs, commercial, and access each feel urgency before approval—but they optimize different horizons. MA wants scientific depth and relationships; commercial wants messaging and segmentation; access wants budget impact and comparators. Without a shared evidence spine, teams produce parallel slide decks, conflicting claims, and field materials that must be rewritten the day after label. Meanwhile, payers begin forming expectations from public data, congress presentations, and KOL chatter long before formulary reviews open.

Effective pre-launch strategy aligns those clocks. It defines what can be said at each milestone, what evidence still belongs in confidential advisory settings, and what must wait for the label. It also connects pre-launch education to post-launch ISS and RWE so the first wave of publications does not paint you into a corner.

Where we focus

Medical affairs and scientific engagement

We help design advisory boards, steering committees, and publication cascades that build credible experts without overstepping data. MSL narratives, slide architecture, and medical information FAQs are drafted with explicit tiers: registrational fact, contextual epidemiology, and speculative science—each with guardrails.

Disease burden and unmet need

We synthesize epidemiology, treatment patterns, and humanistic burden into materials that support both HCP empathy and payer relevance. The goal is consistency: the same figures and definitions appear in internal training, external education, and early access conversations.

Evidence gaps and launch sequencing

We map what the registrational package will and will not support on day one, then sequence ISS, RWE, and health economics so launch teams know which claims require immediate study investment versus later lifecycle support.

Cross-functional alignment

We facilitate workshops with commercial, MA, access, and HEOR on objection handling, competitive counterpoints, and segmentation hypotheses—always tied back to evidence status. Outputs include decision logs and versioned narrative bibles to reduce drift as agencies and data evolve.

What we deliver

• Pre-launch medical affairs plans: KOL maps, congress strategy, and publication roadmaps.
• Scientific platform and narrative architecture with claim tiers and evidence citations.
• MSL and medical information content outlines aligned to anticipated label scenarios.
• Early payer and HTA landscape memos connecting clinical data to likely review questions.
• Evidence gap analyses bridging registrational trials to post-launch study portfolios.
• Workshop design and facilitation for launch team readiness and governance checkpoints.

Outcomes you can expect

• Less scramble after label because narratives were pre-tested against multiple approval scenarios.
• Fewer contradictions between field, medical, and access-facing materials.
• Clearer investment decisions on ISS and RWE before launch budgets crystallize.
• Stronger trust with KOLs and advocates because engagement was sequenced responsibly.

How we work

Pre-launch is where optimism and discipline collide. lotor lab helps teams build excitement without boxing the label or promising access outcomes the dossier cannot support. We use the same constellation-of-evidence mindset as regulatory work—aimed at prescribers, payers, and patients.

We partner with your medical directors and franchise leads; we do not replace medical affairs ownership of external engagement. Our value is integration under uncertainty: multiple label scenarios, shifting readouts, and competitive noise.

When teams bring us in

• 12–18 months before PDUFA or expected approval, when MA and access plans are still elastic.
• After pivotal readouts that change differentiation, endpoint emphasis, or safety narrative.
• Rare, pediatric, or stigmatized diseases where advocacy and KOL sequencing are sensitive.
• When prior launches suffered from message drift between global and US teams.